Nuvation Bio Company Insiders
| NUVB Stock | USD 5.86 0.04 0.68% |
About 75% of Nuvation Bio's corporate insiders are selling. The analysis of the overall insider sentiment regarding Nuvation Bio suggests that many insiders are alarmed. Nuvation Bio employs about 291 people. The company is managed by 22 executives with a total tenure of roughly 88 years, averaging almost 4.0 years of service per executive, having 13.23 employees per reported executive.
Insider Sentiment 25
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-12-01 | Dongfang Liu | Disposed 150000 @ 7.82 | View | ||
| 2025-11-26 | Dongfang Liu | Disposed 10000 @ 8 | View | ||
| 2025-11-19 | Dongfang Liu | Disposed 15000 @ 5.1 | View | ||
| 2025-11-17 | Dongfang Liu | Disposed 15000 @ 4.76 | View | ||
| 2025-10-27 | Gary Hattersley | Disposed 100000 @ 5.02 | View | ||
| 2025-05-02 | Dongfang Liu | Disposed 20000 @ 2.5 | View | ||
| 2025-04-07 | David Hung | Acquired 300000 @ 1.62 | View | ||
| 2025-04-04 | David Hung | Acquired 200000 @ 1.66 | View |
Monitoring Nuvation Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvation Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Nuvation Bio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Nuvation Bio's future performance. Based on our forecasts, it is anticipated that Nuvation will maintain a workforce of about 290 employees by March 2026.Nuvation Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.2482) % which means that it has lost $0.2482 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5249) %, meaning that it created substantial loss on money invested by shareholders. Nuvation Bio's management efficiency ratios could be used to measure how well Nuvation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of February 5, 2026, Return On Tangible Assets is expected to decline to -1. The current year's Return On Capital Employed is expected to grow to -1.34. At present, Nuvation Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 8.8 M, whereas Total Assets are forecasted to decline to about 464.1 M.As of February 5, 2026, Common Stock Shares Outstanding is expected to decline to about 237.3 M. The current year's Net Loss is expected to grow to about (89.1 M)Nuvation Bio maintains a total of 341.83 Million outstanding shares. Over half of Nuvation Bio's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 340.7 M | Current Value 342.4 M | Avarage Shares Outstanding 230.9 M | Quarterly Volatility 52.4 M |
Nuvation Bio Workforce Comparison
Nuvation Bio is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,516. Nuvation Bio retains roughly 291 in number of employees claiming about 12% of equities under Health Care industry.
Nuvation Bio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nuvation Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-12-01 | 0.4211 | 8 | 19 | 864,051 | 1,709,051 |
| 2025-09-01 | 1.0 | 1 | 1 | 350,001 | 350,001 |
| 2025-06-01 | 8.5 | 17 | 2 | 2,702,215 | 40,000 |
| 2024-12-01 | 3.0 | 3 | 1 | 850,000 | 56,361 |
| 2024-09-01 | 9.5 | 19 | 2 | 25,069,314 | 145,749 |
| 2024-06-01 | 8.0 | 16 | 2 | 11,337,090 | 659,947 |
| 2024-03-01 | 8.0 | 8 | 1 | 5,491,179 | 0.00 |
| 2022-09-01 | 9.0 | 9 | 1 | 3,489,500 | 0.00 |
| 2022-06-01 | 7.0 | 14 | 2 | 1,901,337 | 5,000,000 |
| 2021-12-01 | 1.1429 | 8 | 7 | 456,400 | 5,255,036 |
| 2021-09-01 | 1.0 | 1 | 1 | 56,598 | 56,598 |
| 2021-03-01 | 2.4211 | 46 | 19 | 88,294,946 | 11,373,505 |
Nuvation Bio Notable Stakeholders
A Nuvation Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nuvation Bio often face trade-offs trying to please all of them. Nuvation Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nuvation Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Hung | President, Chief Executive Officer, Founder, Director | Profile | |
| Junyuan Wang | CEO Therapeutics | Profile | |
| Jennifer Fox | Chief Financial Officer | Profile | |
| Moses CPA | VP Officer | Profile | |
| Stephen Dang | VP Secretary | Profile | |
| W Vernon | Independent Director | Profile | |
| Michelle Doig | Independent Director | Profile | |
| Gary Hattersley | Chief Scientific Officer | Profile | |
| Moses Makunje | Principal Officer | Profile | |
| Robert Bazemore | Independent Director | Profile | |
| Kerry Wentworth | Chief Officer | Profile | |
| Daniel Welch | Independent Chair of the Board | Profile | |
| Colleen Sjogren | Chief Officer | Profile | |
| David Hanley | Chief Technical Operations Officer | Profile | |
| Thomas Templeman | Senior Vice President - Pharmaceutical Operations and Quality | Profile | |
| Stacy Markel | Senior Vice President - Human Resources | Profile | |
| Kathryn Falberg | Independent Director | Profile | |
| Oleg Nodelman | Director | Profile | |
| Kim Blickenstaff | Independent Director | Profile | |
| Philippe Sauvage | Chief Officer | Profile | |
| Sergey Yurasov | Chief Medical Officer | Profile | |
| David MD | President, Founder | Profile |
About Nuvation Bio Management Performance
The success or failure of an entity such as Nuvation Bio often depends on how effective the management is. Nuvation Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nuvation management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nuvation management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.95) | (1.00) | |
| Return On Capital Employed | (1.41) | (1.34) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | (1.41) | (1.34) |
Please note, the presentation of Nuvation Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nuvation Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nuvation Bio's management manipulating its earnings.
Nuvation Bio Workforce Analysis
Traditionally, organizations such as Nuvation Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nuvation Bio within its industry.Nuvation Bio Manpower Efficiency
Return on Nuvation Bio Manpower
| Revenue Per Employee | 27.1K | |
| Revenue Per Executive | 357.9K | |
| Net Loss Per Employee | 2M | |
| Net Loss Per Executive | 25.8M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 21.3M |
Complementary Tools for Nuvation Stock analysis
When running Nuvation Bio's price analysis, check to measure Nuvation Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvation Bio is operating at the current time. Most of Nuvation Bio's value examination focuses on studying past and present price action to predict the probability of Nuvation Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvation Bio's price. Additionally, you may evaluate how the addition of Nuvation Bio to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |